Johnson & Johnson

Johnson & Johnson recalls Simponi devices

Tuesday, March 1, 2011 08:00 AM

Johnson & Johnson has recalled Simponi injection devices because of their potential to deliver a substandard dose of the arthritis treatment, according to a report in Fierce Pharma.

More... »

ERT names Eric Schwartz chief legal officer

Tuesday, March 1, 2011 08:00 AM

eResearchTechnology, a provider of clinical services and medical devices to biopharmaceutical and healthcare organizations, has named Eric Ian Schwartz executive vice president and chief legal officer.

More... »

Competition aims to recognize, reward skilled U.S. clinical researchers and raise industry profile

Monday, January 24, 2011 12:06 PM

Clinical research associates, study nurses, trial managers and clinical research teams have a chance to win $1,000 prizes in a competition designed to measure their technical and interpersonal skills in a changing global industry and raise the profile of clinical research in the United States.

More... »

ProPublica report: big pharma paid hundreds of physicians over $100,000 in speaking fees

Monday, November 8, 2010 11:12 AM

Several doctors paid to speak on behalf of big pharmaceutical companies aren’t, in fact, the thought leaders consumers often consider them to be, but instead have been sanctioned for various forms of misconduct. And psychiatrists collect more in speaking and consulting fees from pharma companies than doctors in any other specialty.

More... »

WuXi Partners with Janssen to Meet GLP Standards in China Lab

Thursday, March 4, 2010 06:10 AM

Chinese CRO WuXi PharmaTech expanded its strategic collaboration with Johnson & Johnson Pharmaceutical Research and Development(a division of Janssen Pharmaceutica) to provide preclinical services to Janssen and to eventually offer Good Laboratory Practice (GLP) toxicology services at WuXi’s facility in Suzhou, China.

More... »

WuXi Revenues Up 98%, Still Fall Short

Thursday, November 13, 2008 10:14 AM

WuXi Pharmatech released final third quarter earnings that reflected 98% revenue growth year-over-year but fell short of the company’s projected Q3 earnings.

More... »